{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:19:39Z","timestamp":1788261579166,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.yrtph.2019.104429","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T02:18:45Z","timestamp":1563329925000},"page":"104429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates"],"prefix":"10.1016","volume":"107","author":[{"given":"Haleh","family":"Saber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany K.","family":"Ricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Leighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.yrtph.2019.104429_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.yrtph.2019.104429_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061694","article-title":"TSPO: an evolutionarily conserved protein with elusive functions","volume":"19","author":"Bonsack","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.yrtph.2019.104429_bib4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1208\/s12248-015-9738-4","article-title":"Antibody drug conjugates: preclinical considerations","volume":"17","author":"Bornstein","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.yrtph.2019.104429_bib1","author":"ClinicalTrials.gov Identifier (SG2000): NCT02034227"},{"key":"10.1016\/j.yrtph.2019.104429_bib5","author":"ClinicalTrials.gov Identifiers (SJG-136): NCT00103220; NCT00121290; NCT00103220; NCT00121290"},{"issue":"2","key":"10.1016\/j.yrtph.2019.104429_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ph11020032","article-title":"Antibody-drug conjugates for cancer therapy: chemistry to clinical implications","volume":"11","author":"Dan","year":"2018","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.yrtph.2019.104429_bib7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.intimp.2010.08.015","article-title":"Effects of different doses and schedules of diazepam treatment on lymphocyte parameters in rats","volume":"10","author":"de Lima","year":"2010","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.yrtph.2019.104429_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs"},{"issue":"6","key":"10.1016\/j.yrtph.2019.104429_bib9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40259-017-0254-1","article-title":"Recent developments in ADC technology: preclinical studies signal future clinical trends","volume":"31","author":"Drake","year":"2017","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.yrtph.2019.104429_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2478\/v10102-011-0021-y","article-title":"Differential effects of alprazolam and clonazepam on the immune system and blood vessels of non-stressed and stressed adult male albino rats","volume":"4","author":"Elmesallamy","year":"2011","journal-title":"Interdiscip. Toxicol."},{"issue":"11","key":"10.1016\/j.yrtph.2019.104429_bib11","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a Pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.yrtph.2019.104429_bib12","author":"Genentech"},{"key":"10.1016\/j.yrtph.2019.104429_bib13","author":"Genentech"},{"issue":"6","key":"10.1016\/j.yrtph.2019.104429_bib15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/13543784.2011.573477","article-title":"The development of pyrrolobenzodiazepines as antitumour agents","volume":"20","author":"Hartley","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.yrtph.2019.104429_bib16","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.yrtph.2019.104429_bib17","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/1078-0432.CCR-08-1315","article-title":"Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors","volume":"15","author":"Hochhauser","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yrtph.2019.104429_bib18","author":"ICH"},{"key":"10.1016\/j.yrtph.2019.104429_bib19","author":"ICH"},{"issue":"5","key":"10.1016\/j.yrtph.2019.104429_bib20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00280-009-1088-4","article-title":"A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors","volume":"65","author":"Janjigian","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.yrtph.2019.104429_bib21","first-page":"3153","article-title":"Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma","volume":"130","author":"Kinneer","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.yrtph.2019.104429_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091486","article-title":"Regulation of Translocator Protein 18 kDa (TSPO) expression in rat and human male germ cells","volume":"17","author":"Manku","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yrtph.2019.104429_bib23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody\u2013drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Chem. Int. Ed."},{"issue":"5","key":"10.1016\/j.yrtph.2019.104429_bib24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1208\/s12248-015-9790-0","article-title":"Antibody drug conjugates: nonclinical safety considerations","volume":"17","author":"Masson Hinrichs","year":"2015","journal-title":"AAPS J."},{"issue":"19","key":"10.1016\/j.yrtph.2019.104429_bib25","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-17-0219","article-title":"Fractionated dosing improves preclinical therapeutic index of pyrrolobenzodiazepine-containing antibody drug conjugates","volume":"23","author":"Masson Hinrichs","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.yrtph.2019.104429_bib26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","article-title":"Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry","volume":"17","author":"McCombs","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.yrtph.2019.104429_bib27","article-title":"MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies","volume":"vol. 78","author":"Monks","year":"2018"},{"issue":"3","key":"10.1016\/j.yrtph.2019.104429_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/08923978609026493","article-title":"Effect of benzodiazepine derivatives: I. Augmentation of T cell-dependent antibody response by diazepam in mouse spleen cells","volume":"8","author":"Okimura","year":"1986","journal-title":"J. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2019.104429_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1124\/pr.114.009373","article-title":"Antibody drug conjugates for cancer therapy","volume":"68","author":"Polakis","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.yrtph.2019.104429_bib30","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-10-2056","article-title":"Phase I, pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors","volume":"17","author":"Puzanov","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.yrtph.2019.104429_bib31","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","article-title":"Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies","volume":"77","author":"Rios-Doria","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.yrtph.2019.104429_bib32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.yrtph.2013.08.017","article-title":"Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology","volume":"67","author":"Roberts","year":"2013","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2019.104429_bib33","first-page":"444","article-title":"An FDA oncology analysis of antibody-drug conjugates Regul","volume":"71","author":"Saber","year":"2015","journal-title":"Toxicol. Pharmacol."},{"issue":"302","key":"10.1016\/j.yrtph.2019.104429_bib34","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.yrtph.2019.104429_bib14","author":"Seattle Genetics"},{"issue":"2","key":"10.1016\/j.yrtph.2019.104429_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-2999(00)00760-3","article-title":"Anti-inflammatory effects of peripheral benzodiazepine receptor ligands in two mouse models of inflammation","volume":"408","author":"Torres","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.yrtph.2019.104429_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091860","article-title":"Development and properties of valine-alanine based antibody-drug conjugates with monomethyl auristatin E as the potent payload","volume":"18","author":"Wang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yrtph.2019.104429_bib37","author":"Wyeth Pharms Inc"},{"key":"10.1016\/j.yrtph.2019.104429_bib38","author":"Wyeth Pharms Inc"},{"issue":"22","key":"10.1016\/j.yrtph.2019.104429_bib39","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1182\/blood.V128.22.4176.4176","article-title":"hLL2-Cys-PBD, a new site-specifically conjugated, pyrrolobenzodiazepine (PBD) dimer-based antibody drug conjugate (ADC) targeting CD22-expressing B-cell malignancies","volume":"128","author":"Zammarchi","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.yrtph.2019.104429_bib40","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"a). ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.yrtph.2019.104429_bib41","article-title":"b). ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors","volume":"vol. 78","author":"Zammarchi","year":"2018"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323001930193X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027323001930193X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:29:10Z","timestamp":1759494550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027323001930193X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":41,"alternative-id":["S027323001930193X"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.104429","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.104429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104429"}}